Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zodasiran in Adolescents with Homozygous Familial Hypercholesterolemia
NCT07473843Phase 3Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
A Phase 3 trial of zodasiran in homozygous familial hypercholesterolemia (HoFH), sponsored by Arrowhead Pharmaceuticals. Started Oct 2026; status: recruiting.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT07473843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473843.